Active	Status	Sponsor type	Region	Phase	Filter
4 Active 2 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Anderson, Paul
BCG+MMC, NCT02948543: Adding Mitomycin to BCG as Adjuvant Intravesical Therapy for High-risk Non-Muscle-invasive Bladder Cancer	Active, not recruiting	3	501	Europe, RoW	Bacillus of Calmette-Guerin (BCG), OncoTICE, ImmuCYST, TheraCys, Mitomycin (MM)	University of Sydney, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Cancer Australia	Bladder Cancer	12/24	12/24
NCT06351904: A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy	Recruiting	1	15	RoW	RAG-01	Ractigen Therapeutics.	Non-Muscle-Invasive Bladder Cancer (NMIBC)	06/25	08/25
ZEST EU, NCT03577236: The Zenflow Spring System EU Safety and Performance Study	Recruiting	N/A	50	RoW	Zenflow Spring System, Spring Implant	Zenflow, Inc.	Benign Prostatic Hyperplasia	12/22	05/24
VAPEUR RCT, NCT04838769: REZŪM vs. Dual Drug Therapy for Symptomatic Benign Prostatic Hyperplasia in Sexually Active Men	Active, not recruiting	N/A	154	Europe, RoW	REZŪM, alpha blocker and 5-alpha reductase inhibitor, Dual Drug Therapy	Boston Scientific Corporation	Benign Prostatic Hyperplasia (BPH)	02/26	03/27